This review assessed different strategies for discontinuing long-term benzodiazepine use. The authors concluded that stepped care (minimal intervention followed by systematic discontinuation alone) is effective in discontinuing longterm use. This conclusion was not derived directly from the data presented in the paper, and it excludes some information on effective strategies that include medication. It should therefore be viewed with caution.
Data extraction
Two reviewers independently extracted the data from the included studies. Interventions were categorised by each reviewer, and any disagreements were resolved by discussion. Dosages in diazepine equivalents were calculated where possible. Where insufficient information was presented, dosages were categorised as low (within therapeutic range or less than 15 mg), high (above therapeutic range or more than 30 mg), or medium (within and above therapeutic range or 15 to 30 mg). Odds ratios (ORs) and corresponding confidence intervals (CIs) were calculated for each study.
Methods of synthesis
How were the studies combined? The studies were combined in a meta-analysis using fixed-effect methods; a random-effects method was used where statistical heterogeneity was found. Summary estimates for success rates were presented as ORs with 95% CIs, grouped by intervention type and comparator, and further sub-grouped by drug for studies which included medication in the intervention.
How were differences between studies investigated?
The authors indicated that statistical heterogeneity was assessed but did not report how it was evaluated.
Results of the review
Twenty-nine RCTs, providing 34 data sets, were included in the review (n=2,398 in total): 3 minimal intervention (n=526), 1 systematic discontinuation alone (n=84), 5 systematic discontinuation with psychotherapy (n=342) and 25 systematic discontinuation with medication (n=1,261).
The quality of the included studies was deemed to be moderate to excellent: the total scores ranged from 8 to 17.
Benzodiazepine discontinuation strategies.
A significantly higher discontinuation success rate was found in those receiving minimal intervention compared with usual care (OR 2.8, 95% CI: 1.6, 5.1), based on 3 studies (n=526). No statistical heterogeneity was found.
One study, which compared systematic discontinuation alone with usual care (n=84), found a significantly higher discontinuation success rate in those receiving systematic discontinuation (OR 6.1, 95% CI: 2.0, 18.6).
Benzodiazepine discontinuation augmentation strategies. A higher success rate was found for systematic discontinuation with psychotherapy compared with systematic discontinuation alone (OR 1.8, 95% CI: 1.1, 2.9), based on 5 studies (n=342). Statistically significant between-study heterogeneity was present.
Systematic discontinuation with medication (21 studies, 25 data sets, n=1,261).
Significantly higher discontinuation success rates were found in patients receiving systematic discontinuation plus imipramine (OR 3.1, 95% CI: 1.1, 9.4, p=0.03), while higher success rates of borderline significance were found in patients receiving systematic discontinuation plus carbamazopine (OR 3.5, 95% CI: 0.9, 16.7, p=0.06), compared with those receiving systematic discontinuation alone; based on 3 studies (n=94) and 2 studies (n=75), respectively. No statistical heterogeneity was found. No significant difference in the discontinuation rates was found between groups for systematic discontinuation augmented with trazodone, propranolol or buspirone compared with systematic discontinuation alone. Statistical heterogeneity was found in the studies evaluating augmentation with propranolol and buspirone. The authors reported that this heterogeneity was explained by differences in the tapering procedure (propranolol only), transfer to long-acting agent, baseline benzodiazepine dosage, type of benzodiazepine, and the diagnosis of included patients (propranolol and buspirone).
Eleven studies evaluated systematic discontinuation with a different single pharmacological agent (aldpidem, progesterone, dothiepin, hydroxyzine, melatonin, Asp Mg, valproate, homeogene 46, sedative PC, paroxetine and 
